옛 화면은 좌우로 밀어 볼 수 있습니다.

▒▒▒▒ 보건복지부 약물대사유전체연구센터 ▒▒▒▒
 
 
 

 

HOME < 연구성과 < 논문실적
 
   
 
년도별 분류:
Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG.
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. (PRCDM )
    Clin Pharmacol Ther 2006;79:590-9 [LINK]
Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW.
Sequence-based CYP2D6 genotyping in the Korean population. (PRCDM )
    Ther Drug Monit 2006;28:382�387 [LINK]
Kang HJ, Lee SS, Lee CH, Shim JC, Shin HJ, Liu KH, Yoo MA, Shin JG.
Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. (NRL, PRCDM )
    DMD 34:1145�1151, 2006 [LINK]
Park JY,Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, Cha IJ, and Shin JG
Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects (PRCDM )
    Journal of Clinical Psychopharmacology, Volume 26, Number 2, April 2006 [LINK ]
Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, Liu KH.
Inhibitory effects of fruit juices on cyp3a activity. (NRL, PRCDM )
    Drug Metab Dispos. 2006 Apr;34(4):521-3. Epub 2006 Jan 13. [LINK]
Liu KH, Kim MJ, Jeon BH, Shon JH, Cha IJ, Cho KH, Lee SS, Shin JG.
Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. (PRCDM )
    J Clin Pharm Ther. 2006 Feb;31(1):83-91. [LINK]
Kim H, Kang S, Kim H, Yoon YJ, Cha EY, Lee HS, Kim JH, Yea SS, Lee SS, Shin JG, Liu KH.
In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. (FRONTIER, PRCDM )
    Rapid Commun Mass Spectrom. 2006;20(5):837-43. [LINK]
Liu KH, Lee YK, JY, Lee DJ, Kang WK, Lee SS, Yoon YR, Shin JG.
Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column (PRCDM )
    Chromatographia, 2004, 60/639~643 [LINK]
Park JY, Kim KA, Shin JG, Lee KY.
Effect of ketoconazole on the pharmacokinetics of resiglitazone in healthy subjects (PRCDM )
    Br J Clin Pharmacol, 2004, 58/397~402 [LINK]
Yu KS, Cho JY, Jang IJ, Hong KS, Chung J, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG.
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (PRCDM )
    Clin Pharmacol Ther, 2004, 76/104~112 [LINK]

 1  2  3  4  5  6